A195940 Stock Overview
Engages in the pharmaceutical business in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A195940 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
HK inno.N Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩35,900.00 |
| 52 Week High | ₩52,000.00 |
| 52 Week Low | ₩34,300.00 |
| Beta | 0 |
| 1 Month Change | -8.54% |
| 3 Month Change | -26.58% |
| 1 Year Change | -12.55% |
| 3 Year Change | -33.02% |
| 5 Year Change | n/a |
| Change since IPO | -47.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| A195940 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -3.2% | -1.7% | -3.7% |
| 1Y | -12.5% | 0.1% | -10.4% |
Return vs Industry: A195940 underperformed the KR Pharmaceuticals industry which returned 0.1% over the past year.
Return vs Market: A195940 underperformed the KR Market which returned -10.4% over the past year.
Price Volatility
| A195940 volatility | |
|---|---|
| A195940 Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A195940 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A195940's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | n/a | Dal-Won Kwak | www.inno-n.com |
HK inno N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, non-small cell lung cancer, and mesothelioma, and colorectal cancer; and nutrition and intravenous nutrition.
HK inno.N Corporation Fundamentals Summary
| A195940 fundamental statistics | |
|---|---|
| Market cap | ₩1.02t |
| Earnings (TTM) | ₩41.49b |
| Revenue (TTM) | ₩839.63b |
0.0x
P/E Ratio0.0x
P/S RatioIs A195940 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A195940 income statement (TTM) | |
|---|---|
| Revenue | ₩839.63b |
| Cost of Revenue | ₩491.45b |
| Gross Profit | ₩348.18b |
| Other Expenses | ₩306.69b |
| Earnings | ₩41.49b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A195940 perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 07:50 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HK inno.N Corporation is covered by 18 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Dae Woong Yoo | Bookook Securities Co. Ltd |
| Jisoo Lee | DAOL Investment & Securities Co., Ltd. |
| Myung Sun Lee | DB Financial Investment Co. Ltd. |